Health-related quality of life (HRQOL) is not negatively impacted by therapy of MK-5172/MK-8742 during treatment of genotype (GT) 1 chronic hepatitis C in contrast to pegylated-interferon (IFN) or ribavirin (RBV)-containing therapy

被引：0
|
作者：
Arduino, Jean Marie [1 ]
Zhang, Boan [1 ]
Nwankwo, Chizoba [1 ]
Khawaja, Shazia [1 ]
Shaughnessy, Melissa [1 ]
Gendrano, Isaias N. [1 ]
Hwang, Peggy [1 ]
Robertson, Michael [1 ]
Mobashery, Niloufar [1 ]
Haber, Barbara A. [1 ]
机构：
[1] Merck & Co Inc, Whitehouse Stn, NJ USA
来源：
HEPATOLOGY | 2014年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1455
引用
收藏
页码：897A / 898A
页数：2
相关论文
共 31 条
  • [21] RIBAVIRIN DOES NOT IMPACT HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS ON OMBITASVIR/ PARITAPREVIR /RITONAVIR AND DASABUVIR AT THE END OF 12-WEEK TREATMENT IN TREATMENT-NAIVE ADULTS WITH GENOTYPE 1A (GT1A) CHRONIC HEPATITIS C
    Liu, Y.
    Bernstein, D.
    Larsen, L.
    Luo, Y.
    Xie, Y.
    Juday, T.
    VALUE IN HEALTH, 2015, 18 (03) : A227 - A227
  • [22] The inpact of therapy with interferon alfa 2b plus ribavirin on health-related quality of life and work productivity in chronic hepatitis C patients.
    Ware, J
    Bayliss, M
    McHutchison, JG
    Pianko, S
    Cort, S
    Albrecht, J
    Neary, M
    HEPATOLOGY, 1999, 30 (04) : 193A - 193A
  • [23] OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR WITH RIBAVIRIN (RBV) HAS MINIMAL IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) COMPARED WITH PLACEBO DURING 12-WEEK TREATMENT IN TREATMENT-NAIVE ADULTS WITH CHRONIC HEPATITIS C (CHC)
    Liu, Y.
    Larsen, L.
    Zeuzem, S.
    Coakley, E.
    Baran, R.
    Juday, T.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S668 - S668
  • [24] OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR WITH RIBAVIRIN (RBV) HAS MILD IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) COMPARED WITH PLACEBO DURING 12-WEEK TREATMENT IN TREATMENT-EXPERIENCED ADULTS WITH CHRONIC HEPATITIS C (CHC)
    Liu, Y.
    Larsen, L.
    Bourliere, M.
    Baran, R.
    Juday, T.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S661 - S661
  • [25] Evaluation of the health-related quality of life using the 36-item short form health survey in patients with chronic hepatitis C receiving pegylated interferon/ribavirin/telaprevir triple treatment
    Suzuki, Mitsuyuki
    Ishikawa, Toru
    Sakuma, Ai
    Abe, Satoshi
    Abe, Hiroko
    Koyama, Fujiko
    Nakano, Tomomi
    Ueki, Aya
    Noguchi, Hirohito
    Hasegawa, Erina
    Yamagata, Shiori
    Kobayashi, Miki
    Ohashi, Kazutaka
    Hirosawa, Hiroshi
    Fukazawa, Takako
    Maruyama, Yuka
    Yoshida, Toshiaki
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2016, 12 (05) : 3353 - 3358
  • [26] Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels
    Bini, EJ
    Mehandru, S
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (06) : 777 - 785
  • [27] IL28B-CC GENOTYPE-RELATED GENE EXPRESSION DURING TREATMENT OF CHRONIC HEPATITIS C (CH-C) WITH PEGYLATED INTERFERON-ALFA (PEG-IFN) AND RIBAVIRIN (RBV): POTENTIAL MECHANISMS FOR SUSTAINED VIROLOGIC RESPONSE (SVR)
    Younossi, Z. M.
    Estep, J. M.
    Birerdinc, A.
    Stepanova, M.
    Baranova, A.
    Younossi, I.
    Afendy, A.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S534 - S534
  • [28] Health-related quality of life (HRQOL) before and after treatment of genotype 1 (GT1) infection with elbasvir/grazoprevir (EBR/GZR): results from the German hepatitis C registry (DHC-R)
    Hueppe, Dietrich
    Stoehr, Albrecht
    Klinker, Hartwig
    Heyne, Renate
    John, Christine
    Simon, Karl-Georg
    Bilzer, Manfred
    Guenther, Veronika
    Witte, Vanessa
    Cornberg, Markus
    JOURNAL OF HEPATOLOGY, 2020, 73 : S342 - S343
  • [29] Impact of sustained viral response after IFNα-2b plus ribavirin combination therapy or IFNα-2b monotherapy on health-related quality of life in Japanese patients with chronic hepatitis C.
    Fukuhara, S
    Toyota, J
    Tomita, E
    Kanai, K
    HEPATOLOGY, 2001, 34 (04) : 580A - 580A
  • [30] LOW PRE-TREATMENT NUMBERS OF CD4+/PD1+LYMPHOCYTES AND LOW HCV-SPECIFIC IL-10 PRODUCTION DURING THERAPY WITH PEGYLATED-INTERFERON plus RIBAVIRIN PREDICT RESPONSE IN CHILDREN WITH CHRONIC HEPATITIS C
    Carey, I.
    Mendes, A.
    Cebecauerova, D.
    Bansal, S.
    Subramaniam, P.
    Tizzard, S.
    Mieli-Vergani, G.
    Vergani, D.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S266 - S266
1234